Lantheus Holdings Inc
LNTH
Detailliertes Diagramm anzeigen
52.490USD
-0.520-0.98%
Handelsschluss 11/17, 16:00（ET）Kurse um 15 Minuten verzögert
3.48BMarktkapitalisierung
20.75KGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-0.98%
5 Tage
+2.78%
1 Monat
-6.87%
6 Monate
-35.39%
Seit Jahresbeginn
-41.33%
1 Jahr
-31.68%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Lantheus Holdings Inc
Währung: USD Aktualisiert: 2025-11-14Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ sehr gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer schwachen Aktienmarktperformance zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Lantheus Holdings Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
13
Analysten
Kaufen
Aktuelles Rating
80.923
Kursziel
+52.66%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Lantheus Holdings Inc Highlights
HöhepunkteRisiko
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=64.04%)
high_profit_growth
high_profit_growth_desc%!(EXTRA string=1.53B)
valuation_reasonable
valuation_reasonable_desc%!(EXTRA string=PE, string=21.52)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=78.96M, string=9.90%)
institutional_hold%!(EXTRA string=Private Capital)
institutional_hold_desc%!(EXTRA string=Private Capital, string=543.64K)
activity_increase
activity_increase_desc%!(EXTRA string=1.29)
Lantheus Holdings Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Lantheus Holdings Inc Informationen
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
BörsenkürzelLNTH
UnternehmenLantheus Holdings Inc
CEOMr. Brian A. Markison
Websitehttps://www.lantheus.com/
Verwandte Finanzinstrumente
-0.36%
-0.41%
-1.99%
-0.52%
-0.31%
-0.91%
-0.58%
+0.49%
+0.95%
+0.77%
+1.57%
+0.61%
+0.87%
-1.04%
-3.03%
-1.78%
-5.53%
-1.59%
-1.33%
+0.13%Beliebte Symbole
